Ftse Mib
34.728,68
0,93%
DAX
19.473,63
1,32%
S&P 500
5.740,21
-0,09%
NASDAQ
18.080,87
-0,60%
Bitcoin
65.796,88
0,94%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CG Oncology Inc (CGON) CG Oncology Inc (CGON) Notizie

CGON

CG Oncology (CGON)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CGON
DataOraFonteTitoloSimboloCompagnia
31/08/202401:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGONCG Oncology Inc
30/08/202414:00GlobeNewswire Inc.CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:CGONCG Oncology Inc
30/08/202402:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGONCG Oncology Inc
08/08/202414:23GlobeNewswire Inc.CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:CGONCG Oncology Inc
08/08/202412:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGONCG Oncology Inc
08/08/202412:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGONCG Oncology Inc
18/06/202414:00GlobeNewswire Inc.CG Oncology Initiates Expanded Access Program for Cretostimogene GrenadenorepvecNASDAQ:CGONCG Oncology Inc
06/06/202418:14GlobeNewswire Inc.CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBCNASDAQ:CGONCG Oncology Inc
24/05/202414:00GlobeNewswire Inc.CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual MeetingNASDAQ:CGONCG Oncology Inc
09/05/202414:00GlobeNewswire Inc.CG Oncology Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:CGONCG Oncology Inc
03/05/202417:23GlobeNewswire Inc.Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
26/04/202414:00GlobeNewswire Inc.CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024NASDAQ:CGONCG Oncology Inc
24/04/202416:00GlobeNewswire Inc.CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024NASDAQ:CGONCG Oncology Inc
28/03/202413:00GlobeNewswire Inc.CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual MeetingNASDAQ:CGONCG Oncology Inc
27/02/202414:00GlobeNewswire Inc.CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
30/01/202413:00Business WireCG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:CGONCG Oncology Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CGON

La tua Cronologia

BIT
MONC
Moncler
BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
ISP
Intesa Sanpaolo
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
PRY
Prysmian
BIT
SPM
Saipem
BIT
CPR
Davide Campari
BIT
BC
Brunello Cucinelli
BIT
TEN
Tenaris
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network